PRA and newly private WuXi call time on China JV

By Dan Stanton

- Last updated on GMT

Wuxi leavse NYSE in $3.3bn go private deal
Wuxi leavse NYSE in $3.3bn go private deal
WuXi PharmaTech and PRA Health Sciences have ended a three year clinical trial management partnership in China.

In December 2013​, the two contract research organisations (CROs) unveiled plans for a Phase I to IV joint venture (JV) in China, Macau and Hong Kong.

The plan was that WuXi would provide expertise in local regulations and lab capacity, while PRA brought its global reach and IT clout.

But this week the firms called time on the partnership, announcing a restructuring plan which will see the mainland China portion of the JV become a wholly owned subsidiary of WuXi.

PRA will take control of the Hong Kong business.

“WuXi approached us to explore the restructuring of our relationship to better align with their current objectives in China,”​ said PRA’s CEO Colin Shannon.

“This restructuring allows us to continue our strong relationship with WuXi to support our client needs in China and to leverage the business that we have built together.”

Wuxi Private

The break-up should not come as much of a surprise, coming a day after Wuxi went private.

Last month PRA CFO Linda Baddour said the JV was "not performing as I had planned​" during a conference call​ last month.

She also said the partnership was being reassessed in light of WuXi’s plan to go private which was announcedin May​.

Wuxi became a private company last night, two weeks after shareholders agreed the $3.3bn (€3bn) plan put forward by new owners New WuXi Life Science Limited and subsidiary WuXi Merger Limited.

The owners include group affiliates of, or funds managed or advised by Ally Bridge Group, shareholder Hillhouse Fund II, as well as Ge Li, chairman and CEO of WuXi and several other executives.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars